Big Rock Partners Acquisition News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.05.23	NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call (PR Newswire)
27.04.23	NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (PR Newswire)
30.03.23	NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update (PR Newswire)
27.03.23	NRx Pharma: DSMB Advises To Continue Ongoing Trial Of NRX-101 (RTTNews)
27.03.23	NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression (PR Newswire)
17.03.23	NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 (PR Newswire)
09.03.23	NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering (PR Newswire)
22.02.23	NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions - Adds New U.S. Patent to Portfolio (PR Newswire)
13.02.23	NRx Updates FDA Meeting On NRX-101 Development To Treat Bipolar Depression With Suicidality (RTTNews)
13.02.23	NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality (PR Newswire)
02.02.23	NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior (PR Newswire)
19.01.23	NRx Pharma Updates On Interactions With FDA Regarding Path To NDA Submission For NRX-101 (RTTNews)
19.01.23	NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 (PR Newswire)
05.01.23	NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference (PR Newswire)
03.01.23	NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted (PR Newswire)
20.12.22	Relief, NeuroRx End Litigation; NeuroRx Transfers To Relief Formulation Of Aviptadil Product (RTTNews)
20.12.22	Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements (PR Newswire)
05.12.22	NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs (PR Newswire)
02.12.22	NRx Receives Nasdaq Notice of Listing Compliance (PR Newswire)
14.11.22	NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
14.11.22	NRx Pharma To Transfer Aviptadil Development Program Assets To Relief Therapeutics (RTTNews)
14.11.22	Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements (PR Newswire)
10.11.22	NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022 (PR Newswire)
09.11.22	NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process (PR Newswire)
07.11.22	NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing (PR Newswire)
08.09.22	NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference (PR Newswire)
15.08.22	NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise (PR Newswire)
10.08.22	NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022 (PR Newswire)
13.07.22	NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director (PR Newswire)
01.07.22	NRx Pharma: FDA Declines To Issue Emergency Use Authorization For ZYESAMI (RTTNews)
23.06.22	NRx Pharma Says Class Action Suit Against Company Dismissed (RTTNews)
11.06.22	NRx Pharma : FDA Denies Breakthrough Therapy Designation Request For Zyesami (RTTNews)
08.06.22	NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer (PR Newswire)
26.05.22	NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19 (PR Newswire)
19.05.22	NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference (PR Newswire)
16.05.22	NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results (PR Newswire)
12.05.22	NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality (PR Newswire)
10.05.22	NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022 (PR Newswire)
21.04.22	NRx Pharma Files New Breakthrough Therapy Designation Request For ZYESAMI (RTTNews)
21.04.22	NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with ... (PR Newswire)
08.04.22	NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare Conference (PR Newswire)
31.03.22	I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill P... (PR Newswire)
31.03.22	NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial Results (PR Newswire)
28.03.22	NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022 (PR Newswire)
18.03.22	NRx Names Ira Strassberg As CFO (RTTNews)
12.03.22	ROSEN, A TOP RANKED FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses Over $100K to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW (PR Newswire)
09.03.22	NRx Pharmaceuticals Announces Leadership Transition (PR Newswire)
05.03.22	ROSEN, GLOBAL INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP; NRXPW (PR Newswire)
18.02.22	Pre-market Movers: NRGV, ROKU, RDFN, CELZ, SHAK… (RTTNews)
15.02.22	NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Big Rock Partners Acquisition Corp Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten